Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
MOLN Molecular
6.450-0.160-2.42%
Trading Session
01/31 12:15 ET
High
6.460
Open
6.330
Turnover
17.06K
Low
6.330
Pre Close
6.610
Volume
2.65K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Molecular Partners Starts Early-stage Study of Blood Cancer Drug MP0533
Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR : Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company
Molecular Partners AG (NASDAQ:MOLN) Short Interest Update
Molecular Partners AG (NASDAQ:MOLN – Get Rating) was the target of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 11,700 shares, a d
Molecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor Conferences
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs
Molecular Partners Reports Positive Interim Data for Phase 1 Trial of Solid Tumors Treatment
Molecular Stock Rises as MP0317 Shows Promise Versus Solid Tumors in Phase 1 Trial
Molecular Partners Presents Interim Safety And Mechanistic Data From Ongoing Phase 1 Trial Of MP0317 For Treatment of Solid Tumors
First clinical observation of tumor localized CD40 activation provided by MP0317No systemic or dose-limiting toxicities observed, a key parameter for CD40 agentsDose escalation remains ongoing with st
Molecular Partners Announces Acceptance of Oral Presentation at the Annual American Society of Hematology Meeting
Molecular Partners Announces Upcoming Participation in Investor and Scientific Conferences
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers NeuroMetrix (NASDAQ:NURO) shares increased by 23.0% to $3.48 during Monday's pre-market session. The company's market cap stands at $24.8 million.Nutex Health (NASDAQ:NUTX) stock moved upwards
Company Overview
More
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
CEO： Dr. Patrick Amstutz, PhD
Market： NASDAQ
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet